Article Information
History
- August 10, 2021.
Article Versions
- Version 1 (August 8, 2021 - 16:08).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Michael K. Loa,*,#,
- Punya Shrivastava-Ranjana,
- Payel Chatterjeea,
- Mike Flinta,
- James R. Beadleb,
- Nadejda Valiaevab,
- Robert T. Schooleyb,
- Karl Y. Hostetlerb,
- Joel M. Montgomerya and
- Christina Spiropouloua,*
- aViral Special Pathogens Branch, Centers for Disease Control and Prevention, Department of Health and Human Services, Atlanta, Georgia, USA
- bDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, La Jolla, California, USA
- ↵#Address correspondence to: Michael K. Lo: mko2{at}cdc.gov
Posted August 10, 2021.
Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
